Hepatocellular carcinoma and Immunodeficiency

Summary:

Immunodeficiency is found among people with Hepatocellular carcinoma, especially for people who are female, 60+ old.

The study analyzes which people have Immunodeficiency with Hepatocellular carcinoma. It is created by eHealthMe based on reports of 20 people who have Hepatocellular carcinoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Hepatocellular carcinoma?

Hepatocellular carcinoma (liver cancer) is found to be associated with 306 drugs and 733 conditions by eHealthMe. Check the latest studies of Hepatocellular carcinoma.

What is Immunodeficiency?

Immunodeficiency is found to be associated with 852 drugs and 820 conditions by eHealthMe. Check the latest studies of Immunodeficiency.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

20 people who have Hepatocellular Carcinoma and Immunodeficiency are studied.

Would you have Immunodeficiency when you have Hepatocellular carcinoma?

Gender of people who have Hepatocellular Carcinoma and experienced Immunodeficiency *:

female: 60 %
male: 40 %

Age of people who have Hepatocellular Carcinoma and experienced Immunodeficiency *:

Common co-existing conditions for these people *:

Metastases To Lung (cancer spreads to lung): 3 people, 15.00%
High Blood Pressure: 2 people, 10.00%
Diabetes: 2 people, 10.00%
Wound: 1 person, 5.00%
Sleep Disorder: 1 person, 5.00%
Pain: 1 person, 5.00%
Osteoporosis (bones weak and more likely to break): 1 person, 5.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 5.00%
Oesophageal Discomfort (pain or burning feeling behind breast bone): 1 person, 5.00%
Memory Loss: 1 person, 5.00%

Common drugs taken by these people *:

Common symptoms for these people *:

Diarrhea: 9 people, 45.00%
Weight Decreased: 7 people, 35.00%
Weakness: 7 people, 35.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 35.00%
Thrombocytopenia (decrease of platelets in blood): 6 people, 30.00%
Rashes (redness): 6 people, 30.00%
Dry Skin: 5 people, 25.00%
Fever: 5 people, 25.00%
Fatigue (feeling of tiredness): 5 people, 25.00%
Stomatitis (inflammation of mucous membrane of mouth): 4 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Immunodeficiency?

- Check whether Immunodeficiency is associated with a drug or a condition

Related publications that referenced our studies

Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .

Related studies:

Treatments, associated drugs and conditions:

Hepatocellular carcinoma (32,153 reports)
Immunodeficiency (20,688 reports)

All the drugs that are associated with Immunodeficiency:

Immunodeficiency (852 drugs)

All the conditions that are associated with Immunodeficiency:

Immunodeficiency (820 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Immunodeficiency and Hepatocellular carcinoma, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.